PT3122769T - Polipéptidos, células e métodos que envolvem cd16 manipulado - Google Patents

Polipéptidos, células e métodos que envolvem cd16 manipulado

Info

Publication number
PT3122769T
PT3122769T PT157163031T PT15716303T PT3122769T PT 3122769 T PT3122769 T PT 3122769T PT 157163031 T PT157163031 T PT 157163031T PT 15716303 T PT15716303 T PT 15716303T PT 3122769 T PT3122769 T PT 3122769T
Authority
PT
Portugal
Prior art keywords
polypeptides
cells
methods involving
engineered
involving engineered
Prior art date
Application number
PT157163031T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of PT3122769T publication Critical patent/PT3122769T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT157163031T 2014-03-28 2015-03-27 Polipéptidos, células e métodos que envolvem cd16 manipulado PT3122769T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461971996P 2014-03-28 2014-03-28

Publications (1)

Publication Number Publication Date
PT3122769T true PT3122769T (pt) 2023-04-24

Family

ID=52829414

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157163031T PT3122769T (pt) 2014-03-28 2015-03-27 Polipéptidos, células e métodos que envolvem cd16 manipulado

Country Status (9)

Country Link
US (4) US10464989B2 (cg-RX-API-DMAC7.html)
EP (2) EP4227318A1 (cg-RX-API-DMAC7.html)
JP (4) JP6795399B2 (cg-RX-API-DMAC7.html)
CN (2) CN113699159A (cg-RX-API-DMAC7.html)
AU (3) AU2015235852B2 (cg-RX-API-DMAC7.html)
CA (1) CA2944199C (cg-RX-API-DMAC7.html)
ES (1) ES2941679T3 (cg-RX-API-DMAC7.html)
PT (1) PT3122769T (cg-RX-API-DMAC7.html)
WO (1) WO2015148926A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015235852B2 (en) 2014-03-28 2019-08-15 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered CD16
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
PT3371314T (pt) * 2015-11-04 2023-08-31 Fate Therapeutics Inc Modificação genómica de células pluripotentes
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA3007996A1 (en) * 2015-12-09 2017-06-15 Nant Holdings Ip, Llc Compositions and methods for treatment of her2 positive metastatic breast cancer
AU2017207906B2 (en) 2016-01-15 2021-03-11 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
EP3426777B1 (en) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
US20180273903A1 (en) * 2016-12-30 2018-09-27 Celularity, Inc. Genetically modified natural killer cells
US20200283501A1 (en) * 2017-10-26 2020-09-10 Regents Of The University Of Minnesota Recombinant immune cells, methods of making, and methods of use
KR20250048610A (ko) * 2017-12-22 2025-04-09 페이트 세러퓨틱스, 인코포레이티드 향상된 면역 효과기 세포 및 이의 용도
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
JP7575271B2 (ja) 2018-03-29 2024-10-29 フェイト セラピューティクス，インコーポレイテッド 操作された免疫エフェクター細胞およびその使用
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
MX2021006194A (es) 2018-12-02 2021-06-30 Fate Therapeutics Inc Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
US20230355759A1 (en) * 2019-07-31 2023-11-09 Celularity Inc. Populations of natural killer cells comprising a cleavage resistant cd16
WO2021113849A1 (en) * 2019-12-05 2021-06-10 Celularity Inc. Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16
EP4168538A4 (en) * 2020-06-19 2024-03-20 Fate Therapeutics, Inc. COMBINATION OF IPSC-DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4255922A1 (en) 2020-12-03 2023-10-11 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CA3205748A1 (en) * 2021-01-21 2022-07-28 Haishan LI Engineered nk cells and methods of treating cancer
KR102894135B1 (ko) * 2021-09-29 2025-12-04 카오티에스 주식회사 신규한 재조합 Fc 수용체 및 이를 포함하는 세포
CN116948012B (zh) * 2022-04-13 2024-07-26 星奕昂(上海)生物科技有限公司 增强细胞功能的cd16抗剪切突变体
CN116716342A (zh) * 2022-06-22 2023-09-08 南京艾尔普再生医学科技有限公司 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物
WO2024067682A1 (zh) * 2022-09-29 2024-04-04 上海先博生物科技有限公司 工程改造的免疫效应细胞及其组合物和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US121788A (en) * 1871-12-12 Improvement in match-boxes
US6444789B1 (en) 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP2007515185A (ja) 2003-12-22 2007-06-14 カイロン コーポレイション 免疫応答障害に対する処置ストラテジーのための診断法としてのＦｃレセプター多型の使用
EP2112162B1 (en) * 2004-07-10 2015-01-14 Fox Chase Cancer Center Genetically modified human natural killer cell lines
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
MX2008000030A (es) * 2005-07-11 2008-04-02 Macrogenics Inc Metodos para el tratamiento de enfermedad autoinmune utilizando anticuerpos anti-cd16a humanizados.
US20080003225A1 (en) * 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
WO2010040091A1 (en) * 2008-10-03 2010-04-08 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Novel dna nanostructures that promote cell-cell interaction and use thereof
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
AU2015235852B2 (en) 2014-03-28 2019-08-15 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered CD16

Also Published As

Publication number Publication date
CA2944199A1 (en) 2015-10-01
AU2022204134A1 (en) 2022-06-30
US20200017570A1 (en) 2020-01-16
AU2019250155B2 (en) 2022-03-17
AU2022204134B2 (en) 2024-11-28
WO2015148926A9 (en) 2016-11-10
JP2017511135A (ja) 2017-04-20
EP3122769B1 (en) 2023-02-22
AU2019250155A1 (en) 2019-10-31
US20240417441A1 (en) 2024-12-19
CN113699159A (zh) 2021-11-26
AU2015235852B2 (en) 2019-08-15
US20170174743A1 (en) 2017-06-22
CA2944199C (en) 2023-08-15
EP4227318A1 (en) 2023-08-16
ES2941679T3 (es) 2023-05-24
EP3122769A1 (en) 2017-02-01
US11370825B2 (en) 2022-06-28
JP2021035390A (ja) 2021-03-04
WO2015148926A1 (en) 2015-10-01
JP7091423B2 (ja) 2022-06-27
JP7575426B2 (ja) 2024-10-29
JP2022121484A (ja) 2022-08-19
AU2015235852A1 (en) 2016-10-20
US12098182B2 (en) 2024-09-24
US20210332103A1 (en) 2021-10-28
CN106715467A (zh) 2017-05-24
JP6795399B2 (ja) 2020-12-02
US10464989B2 (en) 2019-11-05
JP2025004257A (ja) 2025-01-14
CN106715467B (zh) 2021-07-27

Similar Documents

Publication Publication Date Title
PT3122769T (pt) Polipéptidos, células e métodos que envolvem cd16 manipulado
IL320713A (en) Antibodies, uses and methods
ES3050608T3 (en) Improved reprogramming methods and cell culture platforms
IL250072A0 (en) Transgenic cells for stress cell therapy
IL251194A0 (en) Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
IL252198A0 (en) CD47 antibodies, methods and uses
IL287921A (en) Methods for preparing an extremely dense cell pool
SG11201702795QA (en) Engineered renal tissues, arrays thereof, and methods of making the same
PL3113883T3 (pl) Układ sortujący komórki z wykorzystaniem mikrofabrykowanych składowych
GB201616238D0 (en) Modified T cells
EP3110895A4 (en) Polysilocarb materials, methods and uses
GB2526261B (en) Encoded cells and cell arrays
IL252430A0 (en) Antibodies, uses and methods
PT3186217T (pt) Poliéteres, poliaminas, politioéteres, e métodos para preparação dos mesmos
SG11201704473WA (en) New methods and uses
SG11201800872QA (en) Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
GB201405784D0 (en) Novel methods, polypeptides and uses thereof
GB201408673D0 (en) Medicaments,uses and methods
EP3107996A4 (en) Tscm cells and methods for use
HUE047553T2 (hu) Dextrán-szaccharáz aktivitású protein és alkalmazásai
PT3145831T (pt) Recipiente de montagem e método associado
GB201405715D0 (en) Methods, apparatus and materials
IL257651B (en) Electrochemical asymmetric cell device and methods for operating it
GB201408091D0 (en) Methods and uses
GB201401598D0 (en) Cells, preparation, uses, methods and components